Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 6;10:2121. doi: 10.3389/fimmu.2019.02121

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Loyon, Jary, Salomé, Gomez-Cadena, Galaine, Kroemer, Romero, Trabanelli, Adotévi, Borg and Jandus.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effect of chemotherapy treatments on ILC distribution. Frequencies of ILCtot (A) and ILC subsets (B) were analyzed by flow cytometry in PBMCs from chemotherapy-naïve mCRC patients (baseline) and after 3 months of treatment (TT). The mean frequency of ILCtot for HD is represented by a dashed line. Each patient received either the 5FU/Irinotecan regimen (Folfiri) (baseline/TT matched patients, n = 19), the 5FU/Oxaliplatin regimen (Folfox) (baseline/TT matched patients, n = 40), or the 5FU/Oxaliplatin/Irinotecan regimen (Folfoxiri) (baseline/TT matched patients n = 17). *p < 0.05, **p < 0.005, as determined by Student's t-test.